Reply to Volkman et al. Comment on "Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines 2024, 12, 434"

被引：0
|
作者：
Kohli, Michele [1 ]
Joshi, Keya [2 ]
Beck, Ekkehard [2 ]
Hagiwara, Yuriko [3 ]
Van de Velde, Nicolas [2 ]
Igarashi, Ataru [4 ]
机构：
[1] Quadrant Hlth Econ Inc, 92 Cottonwood Crescent, Cambridge, ON N1T 2J1, Canada
[2] Moderna Inc, 325 Binney St, Cambridge, MA 02142 USA
[3] Moderna Inc, 4-1-1 Toranomon,Kamiyacho,Minato Ku, Tokyo 1056923, Japan
[4] Univ Tokyo, Grad Sch Pharmaceut Sci, 7-3-1 Hongo,Bunkyo Ku, Tokyo 1130033, Japan
来源：
VACCINES | 2024年 / 12卷 / 10期
关键词：
coronavirus; SARS-CoV-2; Japan; COVID-19; vaccination; cost-effectiveness;
D O I：
10.3390/vaccines12101175
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Reply to Jakovac and to Rocha et al.: Can vitamin D prevent or manage COVID-19 illness?
    Slominski, Andrzej T.
    Slominski, Radomir M.
    Goepfert, Paul A.
    Kim, Tae-Kang
    Holick, Michael F.
    Jetten, Anton M.
    Raman, Chander
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2020, 319 (02): : E455 - E457
  • [32] Psychometric properties of the fear of COVID-19 scale in Brazil - a reply to Lin et al. (2022) comments
    de Medeiros, Emerson Diogenes
    Monteiro, Renan Pereira
    da Silva, Paulo Gregorio Nascimento
    Gouveia, Valdiney Veloso
    CURRENT PSYCHOLOGY, 2023, 42 (22) : 19006 - 19008
  • [33] Reply to Alt et al. Comment on "Lunz et al. Impact and Modification of the New PJI-TNM Classification for Periprosthetic Joint Infections. J. Clin. Med. 2023, 12, 1262"
    Lunz, Andre
    Lehner, Burkhard
    Voss, Moritz N.
    Knappe, Kevin
    Jaeger, Sebastian
    Innmann, Moritz M.
    Renkawitz, Tobias
    Omlor, Georg W.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (21)
  • [34] Reply to "Musculoskeletal complications of Covid-19 can contribute to its morbidity and mortality" by Finsterer et al.
    Muthu, Sathish
    JOURNAL OF ORTHOPAEDICS, 2023, 36 : 141 - 141
  • [35] Reply to Boyd et al., "Evidence that remdesivir treatment reduces viral titers in patients with COVID-19"
    Faghihi, Isa
    Yan, Victoria C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (12)
  • [36] The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2024 vaccines in the United Kingdom
    Kohli, Michele
    Maschio, Michael
    Lee, Amy
    Joshi, Keya
    Carroll, Stuart
    Balogh, Orsolya
    van de Velde, Nicolas
    Beck, Ekkehard
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 1359 - 1372
  • [37] Commentary: The impact of Covid-19 on psychopathology in children and young people worldwide - reflections on Newlove-Delgado et al. (2023)
    Cortese, Samuele
    Solmi, Marco
    Correll, Christoph U.
    JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY, 2023, 64 (04) : 641 - 644
  • [38] Reply to Twycross et al. Comment on "Ramos-Rincon et al. Palliative Sedation in COVID-19 End-of-Life Care. Retrospective Cohort Study. Medicina 2021, 57, 873"
    Ramos-Rincon, Jose-Manuel
    Priego-Valladares, Manuel
    MEDICINA-LITHUANIA, 2022, 58 (01):
  • [39] Reply to Supady et al. Comment on: Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry
    J. W. Awori Hayanga
    Critical Care, 27 (1):
  • [40] Timely Treatment and No Change in Thyroid Cancer Mortality During COVID-19 Pandemic. Reply to Nocini et al. No Impact of COVID-19 Pandemic on Early Mortality for Thyroid Cancer in the US. Comment on "Lee et al. Impact of the COVID-19 Pandemic on Thyroid Cancer Surgery. Curr. Oncol. 2024, 31, 3579-3590"
    Lee, Max L.
    Chen, Michelle M.
    CURRENT ONCOLOGY, 2024, 31 (10) : 6270 - 6271
12345